The global Botanical Drug market size is predicted to grow from US$ 38940 million in 2025 to US$ 52060 million in 2031; it is expected to grow at a CAGR of 5.0% from 2025 to 2031.
A botanical drug product is intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease in humans.
A botanical drug product consists of vegetable materials, which may include plant materials, algae, macroscopic fungi, or combinations thereof.
A botanical drug product may be available as (but not limited to) a solution, powder, tablet, capsule, elixir, topical, or injection.
Botanical drug products often have unique features, for example, complex mixtures, lack of a distinct active ingredient, and substantial prior human use. Fermentation products and highly purified or chemically modified botanical substances are not considered botanical drug products.
Global 5 largest manufacturers of Botanical Drug are Buchang Pharmaceuticals, China TCM, Tsumura, Schwabe and Tong Ren Tang, which make up about 30%.
China is the largest market, with a share over 60%. In terms of product type, OTC occupy the largest share of the total market, over 60%. And in terms of application, the largest application is Cardiovascular, followed by Respiratory System and Tumor.
The 鈥淏otanical Drug Industry Forecast鈥� looks at past sales and reviews total world Botanical Drug sales in 2024, providing a comprehensive analysis by region and market sector of projected Botanical Drug sales for 2025 through 2031. With Botanical Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Botanical Drug industry.
This Insight Report provides a comprehensive analysis of the global Botanical Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Botanical Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Botanical Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Botanical Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Botanical Drug.
This report presents a comprehensive overview, market shares, and growth opportunities of Botanical Drug market by product type, application, key players and key regions and countries.
Segmentation by Type:
Prescription Drug
OTC
Segmentation by Application:
Cardiovascular
Tumor
Respiratory System
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Buchang Pharmaceuticals
China TCM
Tsumura
Schwabe
Tong Ren Tang
Jumpcan Pharmaceutical
Guangzhou Baiyunshan Pharmaceutical
Yunnan Baiyao
Tasly Holding Group
Bionorica Se
Huarun 999
Taiji
Weleda
Kwangdong
GW Pharmaceuticals
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Botanical Drug 麻豆原创 Size (2020-2031)
2.1.2 Botanical Drug 麻豆原创 Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Botanical Drug by Country/Region (2020, 2024 & 2031)
2.2 Botanical Drug Segment by Type
2.2.1 Prescription Drug
2.2.2 OTC
2.3 Botanical Drug 麻豆原创 Size by Type
2.3.1 Botanical Drug 麻豆原创 Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Botanical Drug 麻豆原创 Size 麻豆原创 Share by Type (2020-2025)
2.4 Botanical Drug Segment by Application
2.4.1 Cardiovascular
2.4.2 Tumor
2.4.3 Respiratory System
2.4.4 Other
2.5 Botanical Drug 麻豆原创 Size by Application
2.5.1 Botanical Drug 麻豆原创 Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Botanical Drug 麻豆原创 Size 麻豆原创 Share by Application (2020-2025)
3 Botanical Drug 麻豆原创 Size by Player
3.1 Botanical Drug 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global Botanical Drug Revenue by Player (2020-2025)
3.1.2 Global Botanical Drug Revenue 麻豆原创 Share by Player (2020-2025)
3.2 Global Botanical Drug Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Botanical Drug by Region
4.1 Botanical Drug 麻豆原创 Size by Region (2020-2025)
4.2 Global Botanical Drug Annual Revenue by Country/Region (2020-2025)
4.3 Americas Botanical Drug 麻豆原创 Size Growth (2020-2025)
4.4 APAC Botanical Drug 麻豆原创 Size Growth (2020-2025)
4.5 Europe Botanical Drug 麻豆原创 Size Growth (2020-2025)
4.6 Middle East & Africa Botanical Drug 麻豆原创 Size Growth (2020-2025)
5 Americas
5.1 Americas Botanical Drug 麻豆原创 Size by Country (2020-2025)
5.2 Americas Botanical Drug 麻豆原创 Size by Type (2020-2025)
5.3 Americas Botanical Drug 麻豆原创 Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Botanical Drug 麻豆原创 Size by Region (2020-2025)
6.2 APAC Botanical Drug 麻豆原创 Size by Type (2020-2025)
6.3 APAC Botanical Drug 麻豆原创 Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Botanical Drug 麻豆原创 Size by Country (2020-2025)
7.2 Europe Botanical Drug 麻豆原创 Size by Type (2020-2025)
7.3 Europe Botanical Drug 麻豆原创 Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Botanical Drug by Region (2020-2025)
8.2 Middle East & Africa Botanical Drug 麻豆原创 Size by Type (2020-2025)
8.3 Middle East & Africa Botanical Drug 麻豆原创 Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Botanical Drug 麻豆原创 Forecast
10.1 Global Botanical Drug Forecast by Region (2026-2031)
10.1.1 Global Botanical Drug Forecast by Region (2026-2031)
10.1.2 Americas Botanical Drug Forecast
10.1.3 APAC Botanical Drug Forecast
10.1.4 Europe Botanical Drug Forecast
10.1.5 Middle East & Africa Botanical Drug Forecast
10.2 Americas Botanical Drug Forecast by Country (2026-2031)
10.2.1 United States 麻豆原创 Botanical Drug Forecast
10.2.2 Canada 麻豆原创 Botanical Drug Forecast
10.2.3 Mexico 麻豆原创 Botanical Drug Forecast
10.2.4 Brazil 麻豆原创 Botanical Drug Forecast
10.3 APAC Botanical Drug Forecast by Region (2026-2031)
10.3.1 China Botanical Drug 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 Botanical Drug Forecast
10.3.3 Korea 麻豆原创 Botanical Drug Forecast
10.3.4 Southeast Asia 麻豆原创 Botanical Drug Forecast
10.3.5 India 麻豆原创 Botanical Drug Forecast
10.3.6 Australia 麻豆原创 Botanical Drug Forecast
10.4 Europe Botanical Drug Forecast by Country (2026-2031)
10.4.1 Germany 麻豆原创 Botanical Drug Forecast
10.4.2 France 麻豆原创 Botanical Drug Forecast
10.4.3 UK 麻豆原创 Botanical Drug Forecast
10.4.4 Italy 麻豆原创 Botanical Drug Forecast
10.4.5 Russia 麻豆原创 Botanical Drug Forecast
10.5 Middle East & Africa Botanical Drug Forecast by Region (2026-2031)
10.5.1 Egypt 麻豆原创 Botanical Drug Forecast
10.5.2 South Africa 麻豆原创 Botanical Drug Forecast
10.5.3 Israel 麻豆原创 Botanical Drug Forecast
10.5.4 Turkey 麻豆原创 Botanical Drug Forecast
10.6 Global Botanical Drug Forecast by Type (2026-2031)
10.7 Global Botanical Drug Forecast by Application (2026-2031)
10.7.1 GCC Countries 麻豆原创 Botanical Drug Forecast
11 Key Players Analysis
11.1 Buchang Pharmaceuticals
11.1.1 Buchang Pharmaceuticals Company Information
11.1.2 Buchang Pharmaceuticals Botanical Drug Product Offered
11.1.3 Buchang Pharmaceuticals Botanical Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.1.4 Buchang Pharmaceuticals Main Business Overview
11.1.5 Buchang Pharmaceuticals Latest Developments
11.2 China TCM
11.2.1 China TCM Company Information
11.2.2 China TCM Botanical Drug Product Offered
11.2.3 China TCM Botanical Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.2.4 China TCM Main Business Overview
11.2.5 China TCM Latest Developments
11.3 Tsumura
11.3.1 Tsumura Company Information
11.3.2 Tsumura Botanical Drug Product Offered
11.3.3 Tsumura Botanical Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.3.4 Tsumura Main Business Overview
11.3.5 Tsumura Latest Developments
11.4 Schwabe
11.4.1 Schwabe Company Information
11.4.2 Schwabe Botanical Drug Product Offered
11.4.3 Schwabe Botanical Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.4.4 Schwabe Main Business Overview
11.4.5 Schwabe Latest Developments
11.5 Tong Ren Tang
11.5.1 Tong Ren Tang Company Information
11.5.2 Tong Ren Tang Botanical Drug Product Offered
11.5.3 Tong Ren Tang Botanical Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.5.4 Tong Ren Tang Main Business Overview
11.5.5 Tong Ren Tang Latest Developments
11.6 Jumpcan Pharmaceutical
11.6.1 Jumpcan Pharmaceutical Company Information
11.6.2 Jumpcan Pharmaceutical Botanical Drug Product Offered
11.6.3 Jumpcan Pharmaceutical Botanical Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.6.4 Jumpcan Pharmaceutical Main Business Overview
11.6.5 Jumpcan Pharmaceutical Latest Developments
11.7 Guangzhou Baiyunshan Pharmaceutical
11.7.1 Guangzhou Baiyunshan Pharmaceutical Company Information
11.7.2 Guangzhou Baiyunshan Pharmaceutical Botanical Drug Product Offered
11.7.3 Guangzhou Baiyunshan Pharmaceutical Botanical Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.7.4 Guangzhou Baiyunshan Pharmaceutical Main Business Overview
11.7.5 Guangzhou Baiyunshan Pharmaceutical Latest Developments
11.8 Yunnan Baiyao
11.8.1 Yunnan Baiyao Company Information
11.8.2 Yunnan Baiyao Botanical Drug Product Offered
11.8.3 Yunnan Baiyao Botanical Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.8.4 Yunnan Baiyao Main Business Overview
11.8.5 Yunnan Baiyao Latest Developments
11.9 Tasly Holding Group
11.9.1 Tasly Holding Group Company Information
11.9.2 Tasly Holding Group Botanical Drug Product Offered
11.9.3 Tasly Holding Group Botanical Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.9.4 Tasly Holding Group Main Business Overview
11.9.5 Tasly Holding Group Latest Developments
11.10 Bionorica Se
11.10.1 Bionorica Se Company Information
11.10.2 Bionorica Se Botanical Drug Product Offered
11.10.3 Bionorica Se Botanical Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.10.4 Bionorica Se Main Business Overview
11.10.5 Bionorica Se Latest Developments
11.11 Huarun 999
11.11.1 Huarun 999 Company Information
11.11.2 Huarun 999 Botanical Drug Product Offered
11.11.3 Huarun 999 Botanical Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.11.4 Huarun 999 Main Business Overview
11.11.5 Huarun 999 Latest Developments
11.12 Taiji
11.12.1 Taiji Company Information
11.12.2 Taiji Botanical Drug Product Offered
11.12.3 Taiji Botanical Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.12.4 Taiji Main Business Overview
11.12.5 Taiji Latest Developments
11.13 Weleda
11.13.1 Weleda Company Information
11.13.2 Weleda Botanical Drug Product Offered
11.13.3 Weleda Botanical Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.13.4 Weleda Main Business Overview
11.13.5 Weleda Latest Developments
11.14 Kwangdong
11.14.1 Kwangdong Company Information
11.14.2 Kwangdong Botanical Drug Product Offered
11.14.3 Kwangdong Botanical Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.14.4 Kwangdong Main Business Overview
11.14.5 Kwangdong Latest Developments
11.15 GW Pharmaceuticals
11.15.1 GW Pharmaceuticals Company Information
11.15.2 GW Pharmaceuticals Botanical Drug Product Offered
11.15.3 GW Pharmaceuticals Botanical Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.15.4 GW Pharmaceuticals Main Business Overview
11.15.5 GW Pharmaceuticals Latest Developments
12 Research Findings and Conclusion
听
听
*If Applicable.
